Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03742596 |
|
Recruitment Status :
Recruiting
First Posted : November 15, 2018
Last Update Posted : September 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Colorectal cancer (CRC) is one of the most common types of cancer worldwide in general and in Jordan in specific. The studies that investigate the role of Probiotics supplementation in improving the inflammatory response, gastrointestinal toxicity and life quality of patients with colorectal cancer during radiotherapy are limited. So, this study aimed to study the effect of probiotics on the response of inflammatory markers, gastrointestinal toxicity, and quality of life in patients with colorectal cancer during radiation therapy.
An interventional double-blind randomized clinical trial (RCT) design will be used in this study. Forty patients will be recruited and assigned either to receive 3 times a day probiotic supplement or to be control with no intervention. The demographic data, anthropometric measurements, Cancer Quality of Life Questionnaire and blood samples will be collected at baseline and at end of radiation therapy. Interleukin-6, interleukin-1,interleukin-10 IL-10, C-reactive protein, tumor necrosis factor-alpha and complete blood count (CBC) will be measured.
The results will approve or disapprove the beneficial effect of using probiotics as adjuvant therapy for CRC patients and other types of cancer to reduce the side effects of radiotherapy and raise body weight as well as improving their quality of life.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer | Drug: Probiotic Formula Capsule Drug: Placebos | Phase 2 Phase 3 |
To meet the objectives of the study, a control group will be included in parallel with the treatment group in this trail. Forty patients (aged 35-65 years) who recently diagnosed with CRC will be recruited conveniently from the radiation oncology clinic at the King Hussein Cancer Center (KHCC), Amman, Jordan. Patients who meet the inclusion criteria and agree to participate and to take the drug will be allocated to the probiotic supplementation group, while patients who agree to participate but not to receive the drug will be allocated to the control group. The duration of the intervention will be 5 weeks, from the day of radiation until the end of treatment.
For the participants, the King Hussein Cancer Center (KHCC) hospital setting will be utilized for data collection. The patients will be recruited over 12 months and all patients will be asked to sign a written informed consent before enrollment. The patients that will be assigned to the probiotics group (n=20), to receive 3 times a day probiotic supplement. The duration of the intervention (administration of probiotics) will start 10-14 days before radiotherapy and continue over the 5 weeks duration of treatment under the supervision of the treating physician and end with the end of radiation therapy. The blood sample will be collected at baseline and at the end of radiation therapy and 10-14 days after radiation therapy.
The demographic data of each subject will be collected such as; gender, age, body mass index (BMI), tumor location, malignant tumors stage, tumor differentiation, educational level, occupation, family history, smoking, dietary and physical activity. At baseline and end line of the radiation therapy, a Cancer Quality of Life Questionnaire C30 (QLQ-C30) will be collected and blood sample tests will be withdrawn and the following biochemical variables will be measured: immunoglobulin G, immunoglobulin M, immunoglobulin A, interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-1(IL-1), interleukin-10(IL-10), interleukin-12 (IL-12), Tumor necrosis factor-alpha (TNF-α) and complete blood count (CBC).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 40 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy on the Immune System Among Colorectal Cancer Patients |
| Actual Study Start Date : | November 7, 2018 |
| Estimated Primary Completion Date : | September 30, 2022 |
| Estimated Study Completion Date : | December 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Probiotic Formula Capsule
In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
|
Drug: Probiotic Formula Capsule
The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
Other Name: Treatment |
|
Placebo Comparator: Placebos
In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
|
Drug: Placebos
The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 7 weeks.
Other Name: Placebos control |
- The level of Immunoglobulin (Ig) A [ Time Frame: Through study completion, an average of 1 year ]The level of Immunoglobulin (Ig) A in g/L at both baseline and end line of intervention
- The level of Immunoglobulin (Ig) G [ Time Frame: Through study completion, an average of 1 year ]The level of Immunoglobulin (Ig) G in g/L at both baseline and end line of intervention
- The level of Immunoglobulin (Ig) M [ Time Frame: Through study completion, an average of 1 year ]The level of Immunoglobulin (Ig) M in g/L at both baseline and end line of intervention
- The Level of Interleukin (IL)-6 [ Time Frame: Through study completion, an average of 1 year ]The Level of Interleukin (IL)-6 in pg/ml at both baseline and end line of intervention
- The Level of Interleukin (IL)-1 [ Time Frame: Through study completion, an average of 1 year ]The Level of Interleukin (IL)-1 in pg/ml at both baseline and end line of intervention
- The Level of Interleukin (IL)-10 [ Time Frame: Through study completion, an average of 1 year ]The Level of Interleukin (IL)-10 in pg/ml at both baseline and end line of intervention
- The Level of Tumor Necrosis Factor (TNF)-α [ Time Frame: Through study completion, an average of 1 year ]The Level of TNF-α in pg/ml at both baseline and end line of intervention
- The Level of C-reactive protein (CRP) [ Time Frame: Through study completion, an average of 1 yea ]The Level of CRP in mg/ml at both baseline and end line of intervention
- Quality of Life of patients [ Time Frame: Through study completion, an average of 1 year ]The average score of the general quality of life (QoL) subscales assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC-QLQ) which use five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting) range from"Not at A Quite Very" to "Very Much " , and a single global health status/QoL scale range from one (very poor) to 7(Excellent) . In addition, the questionnaire contains five symptom scales that are commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and the perceived financial impact of the disease scale that range from"Not at A Quite Very" to "Very Much ".
- The gastrointestinal toxicity [ Time Frame: Through study completion, an average of 1 year ]Number and percent of participants with treatment-related adverse events as assessed by NCI Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE) change from baseline in the occurrences and grad of Adverse Events on grading scale at 5 Weeks
- The level of White blood cell count (WBC) [ Time Frame: Through study completion, an average of 1 yea ]he level of WBC as cells/ul at both baseline and end line of intervention
- The level of red blood cell count (RBC) [ Time Frame: Through study completion, an average of 1 yea ]The level of RBC as cells/ul at both baseline and end line of intervention
- The mean corpuscular volume (MCV) [ Time Frame: Through study completion, an average of 1 yea ]The MCV in fl at both baseline and end line of intervention
- The mean corpuscular hemoglobin (MCH) [ Time Frame: Through study completion, an average of 1 yea ]The MCH in pg at both baseline and end line of intervention
- The mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: Through study completion, an average of 1 yea ]The MCH in g/dl at both baseline and end line of intervention
- The Platelet count [ Time Frame: Through study completion, an average of 1 yea ]The Platelet count as cells/ ul at both baseline and end line of intervention
- The of Hemoglobin [ Time Frame: Through study completion, an average of 1 yea ]The Hemoglobin in g/dl at both baseline and end line of intervention
- The mean platelet volume (MPV) [ Time Frame: Through study completion, an average of 1 yea ]The MPV in fl at both baseline and end line of intervention
- The level of lymphocytes [ Time Frame: Through study completion, an average of 1 yea ]The number of lymphocytes cells at both baseline and end line of intervention
- The level of Monocytes [ Time Frame: Through study completion, an average of 1 yea ]The number of Monocytes cells at both baseline and end line of intervention
- The level of eosinophils [ Time Frame: Through study completion, an average of 1 yea ]The number of eosinophils cells at both baseline and end line of intervention
- The level of basophils [ Time Frame: Through study completion, an average of 1 yea ]The number of basophils cells at both baseline and end line of intervention
- The level of neutrophils [ Time Frame: Through study completion, an average of 1 yea ]The number of neutrophils cells at both baseline and end line of intervention
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 35 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men or women,
- Aged from 35- 65 years with histologically proven CRC and
- Histologically proven CRC with stage I, II, III
- Will exposed newly to radiotherapy with the absence of any psychological, sociological or geographical condition that potentially affects the compliance with the study protocol and follow-up schedule.
Exclusion Criteria:
- Active infection treated by antibiotic therapy or recent infection or recent antibiotic use;
- Severe cardiovascular and cerebrovascular diseases that could not tolerate radical surgery;
- Recent use of probiotics, prebiotics, or synbiotic;
- Evidence of immunodeficiency;
- Cancer stage IV
- Pregnancy,
- Recent/concurrent admission to ER
- Co-existence of other malignant neoplasms, no other type of cancer in the past 5 years, any serious concomitant systemic disorders or diseases incompatible with the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03742596
| Contact: Lana M Agraib, PhD | +692795152669 | lanamg2007@yahoo.com | |
| Contact: Fawzi Abuhijla, MD,MSc | +69277764888 | FHijle@khcc.jo |
| Jordan | |
| King Hussein Cancer Center | Recruiting |
| Amman, Jordan | |
| Contact: Lana M. Agraib, MSc 00692795125669 lanamg2007@yahoo.com | |
| Contact: Fawzi Abuhijla, MD, MSc 0777648881 FHijle@khcc.jo | |
| Principal Investigator: | Fawzi Abuhijla, MD,MSc | King Hussein Cancer Center | |
| Principal Investigator: | Lana M Agraib, PhD | University of Jordan |
| Responsible Party: | Fawzi Abuhijla, Consultant Radiation Oncologist, King Hussein Cancer Center |
| ClinicalTrials.gov Identifier: | NCT03742596 |
| Other Study ID Numbers: |
19 KHCC 111 |
| First Posted: | November 15, 2018 Key Record Dates |
| Last Update Posted: | September 7, 2020 |
| Last Verified: | September 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | The center (KHCC) where the study conducted emphasis of maintaining privacy and confidentiality of the participants' data |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Colorectal cancer Radiotherapy immune system Inflammatory markers Life quality |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |